ALX hopes to gain insights by tracking EGFR expression in a new trial of ALX2004 and to identify best responders using CD47 expression in a trial of evorpacept.

This clinical study update could impact AstraZeneca’s stock performance positively by showcasing its commitment to innovative cancer treatments. Investors may view this as a strategic move to ...

Explore our latest breakthroughs in Esophageal Cancer Research. Learn more about our innovative pipeline today! @ Esophageal ...

Celldex has stopped development of barzolvolimab in eosinophilic esophagitis (EoE) despite meeting its primary endpoint in a ...

Esophageal carcinoma (EC) is a tumor type of the digestive tract that accounts for about 300,000 deaths worldwide annually, with high aggressiveness and poor prognosis. Chinese researchers have ...

According to The University of Texas MD Anderson Cancer Center, early signs of the cancer include painful swallowing, ...

A California man was diagnosed with cancer after the doctor failed to take his initial symptoms too seriously. Mark Sevillano Jr. has spoken out about getting the crushing news that he had cancer, ...

Gastrointestinal cancers are alarmingly rising in adults under 50, prompting experts to highlight the importance of early ...

Mark Sevillano Jr. 's diagnosis with Stage 2 esophageal cancer is part of a worrisome trend of young people being diagnosed ...

Investing.com -- ProPhase Labs Inc (NASDAQ: PRPH) stock surged 38% after the company announced it has secured a key patent for its biomarker-based system that assesses progression risk in Barrett’s ...

Meanwhile, Esophageal cancer is a unique and complex heterogeneous malignancy, with substantial tumor heterogeneity (13), and TLS at different sites also showed significant heterogeneity, which ...